Antares Pharma Inc (NASDAQ:ATRS) Receives $5.04 Average Target Price from Brokerages

Antares Pharma Inc (NASDAQ:ATRS) has been given a consensus rating of “Buy” by the six research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $5.04.

Separately, BidaskClub downgraded shares of Antares Pharma from a “hold” rating to a “sell” rating in a report on Wednesday, October 9th.

Shares of Antares Pharma stock opened at $3.28 on Friday. Antares Pharma has a 12-month low of $2.53 and a 12-month high of $3.96. The company has a market cap of $536.47 million, a price-to-earnings ratio of -82.00 and a beta of 0.82. The company has a current ratio of 3.46, a quick ratio of 2.87 and a debt-to-equity ratio of 1.01. The company’s 50-day moving average price is $3.38 and its 200-day moving average price is $3.10.

Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.03. Antares Pharma had a negative net margin of 4.03% and a negative return on equity of 9.67%. The firm had revenue of $28.43 million for the quarter, compared to the consensus estimate of $21.66 million. On average, sell-side analysts predict that Antares Pharma will post -0.08 earnings per share for the current year.

Several institutional investors have recently made changes to their positions in the company. Corrado Advisors LLC purchased a new stake in Antares Pharma in the second quarter valued at approximately $26,000. Bank of Montreal Can purchased a new stake in Antares Pharma in the second quarter valued at approximately $45,000. Aperio Group LLC purchased a new stake in Antares Pharma in the second quarter valued at approximately $47,000. Alpine Woods Capital Investors LLC raised its stake in Antares Pharma by 60.0% in the second quarter. Alpine Woods Capital Investors LLC now owns 16,000 shares of the specialty pharmaceutical company’s stock valued at $53,000 after purchasing an additional 6,000 shares in the last quarter. Finally, Prudential Financial Inc. raised its stake in Antares Pharma by 33.8% in the second quarter. Prudential Financial Inc. now owns 18,530 shares of the specialty pharmaceutical company’s stock valued at $61,000 after purchasing an additional 4,680 shares in the last quarter. 38.72% of the stock is currently owned by hedge funds and other institutional investors.

Antares Pharma Company Profile

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Recommended Story: Cost of Capital Explained

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.